Summary
Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.
GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2627293-colon-cancer-pipeline-review-h2-2017
Companies mentioned
3-V Biosciences Inc
4P-Pharma SAS
Actinium Pharmaceuticals Inc
Adamed Sp z oo
Adgero Biopharmaceuticals Holdings Inc
Aduro BioTech Inc
Advanced Cancer Therapeutics LLC
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Affimed GmbH
AGV Discovery SAS
AIMM Therapeutics BV
Ambrx Inc
Amgen Inc
Anavex Life Sciences Corp
AndroScience Corp
ANP Technologies Inc
Aphios Corp
Aposense Ltd
Aptose Biosciences Inc
Asana BioSciences LLC
Aurigene Discovery Technologies Ltd
Batu Biologics Inc
Bayer AG
BCN Biosciences LLC
BeyondSpring Pharmaceuticals Inc
Bicycle Therapeutics Ltd
BioCancell Ltd
Biogazelle NV
Blirt SA
Boehringer Ingelheim GmbH
Can-Fite BioPharma Ltd
CBT Pharmaceuticals Inc
Celgene Corp
Celprogen Inc
Critical Outcome Technologies Inc
CrystalGenomics Inc
CytomX Therapeutics Inc
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Colon Cancer – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 41, 5, 163, 21 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 46 and 17 molecules, respectively.
Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Content: Key Points
Table of Contents 2
Introduction 7
Colon Cancer – Overview 8
Colon Cancer – Therapeutics Development 9
Colon Cancer – Therapeutics Assessment 43
Colon Cancer – Companies Involved in Therapeutics Development 67
Colon Cancer – Drug Profiles 126
Colon Cancer – Dormant Projects 718
Colon Cancer – Discontinued Products 730
Colon Cancer – Product Development Milestones 731
…Continued
ACCESS REPORT @ https://www.wiseguyreports.com/reports/2627293-colon-cancer-pipeline-review-h2-2017
Contact Info:
NORAH TRENT
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Your information will never be shared with any third party.